Perspective Therapeutics, Inc. (NYSE:CATX) CFO Jonathan Robert Hunt Acquires 12,829 Shares

Perspective Therapeutics, Inc. (NYSE:CATX) CFO Jonathan Robert Hunt bought 12,829 shares of the stock in a transaction on Monday, November 25th. The shares were acquired at an average cost of $3.82 per share, for a total transaction of $49,006.78. Following the completion of the transaction, the chief financial officer now directly owns 48,800 shares of the company’s stock, valued at approximately $186,416. The trade was a 35.66 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Perspective Therapeutics Trading Up 18.4 %

Shares of CATX stock opened at $4.37 on Wednesday. Perspective Therapeutics, Inc. has a 52 week low of $2.28 and a 52 week high of $19.05. The business’s fifty day simple moving average is $11.15.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The firm had revenue of $0.37 million during the quarter. As a group, equities analysts predict that Perspective Therapeutics, Inc. will post -0.87 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. nVerses Capital LLC bought a new position in Perspective Therapeutics in the 3rd quarter valued at $57,000. US Bancorp DE raised its holdings in Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares during the last quarter. Intech Investment Management LLC acquired a new position in Perspective Therapeutics during the 3rd quarter valued at about $137,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Perspective Therapeutics in the 3rd quarter valued at about $152,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Perspective Therapeutics during the third quarter worth approximately $153,000. Institutional investors own 54.66% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on CATX. Truist Financial initiated coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price for the company. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $24.00 to $5.00 in a report on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Oppenheimer cut their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. Finally, UBS Group began coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $20.00 target price for the company. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $15.14.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.